IP Library Granted Patent US 10,308,690
Granted Patent B2
US 10,308,690 · App. 14/961,164 · Granted Jun 4, 2019

Mutated immunoglobulin-binding polypeptides

Inventors: Gustav Rodrigo (Uppsala, SE); Mats Ander (Uppsala, SE); Göran Baurén (Uppsala, SE); Tomas Björkman (Uppsala, SE)
Assignee: GE HEALTHCARE BIOPROCESS R&D AB
C07K14/31B01D15/3809B01J20/286B01J20/3204B01J20/3212B01J20/3219B01J20/3274C07K1/22C07K14/745C07K16/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,308,690
App. No.
14/961,164
Granted
Jun 4, 2019
Kind
B2
Abstract

The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, comprising at least the mutation wherein the glutamine residue at position 9 has been mutated to a tryptophan, leucine, glutamic acid, valine or lysine. The invention also discloses multimers of the polypeptide, as well as separation matrices comprising the multimers or polypeptides.

Claims (43)

1. An Fc-binding polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a parental polypeptide, as defined by, or having at least 90% identity to, SEQ ID NO 28, SEQ ID NO 29 or SEQ ID NO 30, comprising at least the mutation wherein the glutamine residue at position 3 has been mutated to leucine, glutamic acid, valine or lysine.

2. A multimer with improved alkaline stability comprising or consisting essentially of a plurality of polypeptide units, which polypeptide comprises a mutant of a parental polypeptide, as defined by, or having at least 90% identity to, SEQ ID NO 28, SEQ ID NO 29 or SEQ ID NO 30, comprising at least the mutation wherein the glutamine residue at position 3 has been mutated to tryptophan, leucine, glutamic acid, valine or lysine.

3. The multimer of claim 2 , wherein the polypeptide units are linked by elements comprising up to 15 amino acids.

4. The multimer of claim 3 , further comprising at the C-terminal or N-terminal one or more coupling element, selected from the group consisting of a cysteine residue, a plurality of lysine residues and a plurality of histidine residues.

5. A separation matrix, comprising a plurality of polypeptides according to claim 1 coupled to a solid support.

6. A separation matrix, comprising a plurality of multimers according to claim 4 coupled to a solid support.

7. The separation matrix of claim 6 , wherein the multimers have been coupled to the solid support via thioether bonds.

8. A method of isolating an immunoglobulin, using a separation matrix according to claim 6 , the method comprising,

a) contacting a liquid sample comprising an immunoglobulin with the separation matrix according to claim 6 ,

b) washing said separation matrix with a washing liquid,

c) eluting the immunoglobulin from the separation matrix with an elution liquid, and

d) cleaning the separation matrix with a cleaning liquid.

9. The method of claim 8 , wherein the cleaning liquid is alkaline.

10. The method of claim 8 , wherein the cleaning liquid comprises 0.1-1.0 M NaOH or KOH.

11. The method of claim 8 , wherein steps a)-d) are repeated at least 50 times.

12. An Fc-binding polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as defined by, or having at least 90% identity to, SEQ ID NO 1 or SEQ ID NO 2, of Protein Z, as defined by, or having at least 90% identity to, SEQ ID NO 3, or of a Protein Z variant as defined by, or having at least 90% identity to, SEQ ID NO 4, comprising at least the mutation wherein the glutamine residue at position 9 has been mutated to leucine, glutamic acid, valine or lysine.

13. A multimer comprising or consisting essentially of a plurality of polypeptide units, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as defined by, or having at least 90% identity to, SEQ ID NO 1 or SEQ ID NO 2, of Protein Z, as defined by, or having at least 90% identity to, SEQ ID NO 3, or of a Protein Z variant as defined by, or having at least 90% identity to, SEQ ID NO 4, comprising at least the mutation wherein the glutamine residue at position 9 has been mutated to tryptophan, leucine, glutamic acid, valine or lysin.

14. A separation matrix, having a plurality of multimers according to claim 13 coupled to a solid support.

15. A method of isolating an immunoglobulin, comprising the steps of:

a) contacting a liquid sample comprising an immunoglobulin with a separation matrix according to claim 14 ,

b) washing said separation matrix with a washing liquid,

c) eluting the immunoglobulin from the separation matrix with an elution liquid, and

d) cleaning the separation matrix with a cleaning liquid.

16. The method of claim 15 , wherein the cleaning liquid comprises 0.1-1.0 M NaOH or KOH.

17. A polypeptide, comprising or consisting essentially of an amino acid sequence selected from the group consisting of: SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 33, SEQ ID NO 34 and SEQ ID NO 35.

18. A separation matrix, having a plurality of polypeptides according to claim 17 coupled to a solid support.

19. A method of isolating an immunoglobulin, comprising the steps of:

a) contacting a liquid sample comprising an immunoglobulin with a separation matrix according to claim 18 ,

b) washing said separation matrix with a washing liquid,

c) eluting the immunoglobulin from the separation matrix with an elution liquid, and

d) cleaning the separation matrix with a cleaning liquid.

20. A multimer with improved alkaline stability comprising or consisting essentially of a plurality of polypeptide units as defined by claim 17 .

21. The multimer of claim 20 , wherein the polypeptide units are linked by elements comprising up to 15 amino acids.

22. The multimer of claim 21 , further comprising at the C-terminal or N-terminal one or more coupling element, selected from the group consisting of a cysteine residue, a plurality of lysine residues and a plurality of histidine residues.

23. A separation matrix, comprising a plurality of multimers according to claim 20 coupled to a solid support.

24. The separation matrix of claim 23 , wherein the multimers have been coupled to the solid support via thioether bonds.

25. A method of isolating an immunoglobulin, using a separation matrix according to claim 23 , the method comprising,

a) contacting a liquid sample comprising an immunoglobulin with the separation matrix according to claim 23 ,

b) washing said separation matrix with a washing liquid,

c) eluting the immunoglobulin from the separation matrix with an elution liquid, and

d) cleaning the separation matrix with a cleaning liquid.

26. The method of claim 25 , wherein the cleaning liquid comprises 0.1-1.0 M NaOH or KOH.

27. The method of claim 23 , wherein steps a)-d) are repeated at least 50 times.

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2015
From: ANDER, MATS; BAUREN, GORAN; BJORKMAN, TOMAS; RODRIGO, GUSTAV
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 037228/0297 →
Priority Claims (2)
SE 1350859 · Jul 10, 2013 · national
SE 1350860 · Jul 10, 2013 · national
Continuity (2)
Continuation In Part PCTSE2014050872 · Jul 8, 2014
Related Publication 20160159857A1 · Jun 9, 2016